stimuvax is out

http://cancerology.blogspot.com/2010/03/stimuvax-is-out.html

Competitors

Two other companies are developing therapeutic lung cancer vaccines. London-based drugmaker GlaxoSmithKline Plc began a final trial of its MAGE-A3 vaccine for lung cancer in 2007.

Transgene SA, the French biotechnology firm backed by the billionaire Merieux family, plans to begin a final test of its TG4010 vaccine this year. The shot, like Stimuvax, targets cancers that express the mucin 1 tumor antigen. Swiss drugmaker Novartis last month bought an option on rights to the experimental vaccine in a deal that may fetch Transgene as much as $960 million.

Transgene dropped 4.4 percent to 17.40 euros in Paris. The company is seeking to raise 150 million euros from investors, according to a report today in France?s Les Echos newspaper.